Human anti-plague monoclonal antibodies protect mice from Yersinia pestis in a bubonic plague model

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Xiao, Xiaodong ^a,d   Zhu, Zhongyu ^a,b   Dankmeyer, Jennifer L ^c   Wormald, Michael M ^c   Fast, Randy L ^c   Worsham, Patricia L ^c   Cote, Christopher K ^c   Amemiya, Kei ^c   Dimitrov, Dimiter S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^d MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; HUMAN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY M252; MONOCLONAL ANTIBODY M253; MONOCLONAL ANTIBODY M254; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG PURIFICATION; DRUG SCREENING; DRUG SPECIFICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; INFECTION PREVENTION; MOUSE; NONHUMAN; PLAGUE; YERSINIA PESTIS; ANIMAL; DISEASE MODEL; IMMUNOLOGY;

MIRIDAE; MURINAE; MUS; YERSINIA PESTIS;

ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; MICE; PLAGUE; YERSINIA PESTIS;

EID: 78149457237     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013047     Document Type: Article

References (37)

1. Perry RD, Fetherston JD (1997) Yersinia pestis - Etiologic agent of plague. Clin Microbiol Rev 10: 35-66.
2. World Health Organization (2003) Human plague in 2000 and 2001. Wkly Epidemiol Rec 78: 130-135.
3. Zilinskas RA (2006) The anti-plague system and the Soviet biological warfare program. Crit Rev Microbiol 32: 47-64.
4. Titball RW, Williamson ED (2004) Yersinia pestis (plague) vaccines. Exp Opin Biol Ther 4: 965-973.
5. Casadevall A (2002) Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emer Infect Dis 8: 833-841.
6. Galimand M, Guiyoule A, Gerbaud G, Rasoamanana B, Chanteau S, et al. (1997) Multidrug resistance in Yersinia pestis mediated by a transferable plasmid. New Eng J of Med 337: 677-680.
7. Welch TJ, Fricke WF, McDermott PF, White DG, Rosso ML, et al. (2007) Multiple antimicrobial resistance in plague: an emerging public health risk. PLoS ONE 2: e309.
8. Heath DG, Anderson GW, Mauro JM, Welkos SL, Andrews GP, et al. (1998) Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine 16: 1131-1137.
9. Williamson ED, Eley SM, Griffin KF, Green M, Russell P, et al. (1995) A New Improved Subunit Vaccine for Plague - the Basis of Protection. Fems Immunol Med Microbiol 12: 223-230.
10. Williamson ED, Flick-Smith HC, LeButt C, Rowland CA, Jones SM, et al. (2005) Human immune response to a plague vaccine comprising recombinant F1 and V antigens. Infect Immun 73: 3598-3608.
11. Anderson GW, Heath DG, Bolt CR, Welkos SL, Friedlander AM (1998) Shortand long-term efficacy of single-dose subunit vaccines against Yersinia pestis in mice. Amer J Trop Med Hyg 58: 793-799.
12. Williamson ED, Vesey PM, Gillhespy KJ, Eley SM, Green M, et al. (1999) An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model. Clin Exper Immunol 116: 107-114.
13. Anderson GW, Worsham PL, Bolt CR, Andrews GP, Welkos SL, et al. (1997) Protection of mice from fatal bubonic and pneumonic plague by passive immunization with monoclonal antibodies against the F1 protein of Yersinia pestis. AmerJ Trop Med Hyg 56: 471-473.
14. Hill J, Leary SEC, Griffin KF, Williamson ED, Titball RW (1997) Regions of Yersinia pestis V antigen that contribute to protection against plague identified by passive and active immunization. Infect Immun 65: 4476-4482.
15. Hill J, Copse C, Leary S, Stagg AJ, Williamson ED, et al. (2003) Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Yersinia pestis. Infect Immun 71: 2234-2238.
16. Park JW, Smolen JS (2001) Monoclonal antibody therapy. In: Scolick M, ed. Drug discovery and designs. San DiegoCA: Academic Press. pp 360-420.
17. Xiao X, Chen W, Feng Y, Zhu Z, Prabakaran P, et al. (2009) Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: Implications for evasion of immune responses and design of vaccine immunogens. Biochem Biophys Res Commun 390: 404-409.
18. Albrecht MT, Li H, Williamson ED, LeButt CS, Flick-Smith HC, et al. (2007) Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax. Infect Immun 75: 5425-5433.
19. Turner A (2001) Antibodies. In: Roitt IM, Brostoff J, Male DK, eds. Immunology. New York, NY. Mosby. pp 65-86.
20. Xiao X, Dimitrov DS (2007) Monoclonal antibodies against viruses and bacteria: a survey of patents. Recent Patents Anti-Infect Drug Disc 2: 171-177.
21. Hwang KYE, Foote J (2005) Immunogenicity of engineered antibodies. Methods 36: 3-10.
22. Cavanaugh DC, Randall R (1959) The role of multiplication of Pasteurella pestis in mononuclear phagocytes in the pathogenesis of flea-borne plague. J Immunol 83: 348-363.
23. Du Y, Rosqvist, Forsberg A (2002) Role of Fraction 1 antigen of Yersinia pestis in inhibition of phagocytosis. Infect Immun 70: 1453-1460.
24. Lawton WD, Erdman RL, Surgalla MJ (1963) Biosynthesis and purification of V and W antigen in Pasterurella pestis. J Immunol 91: 179-184.
25. Broms JE, Francis MS, Forsberg A (2007) Diminished LcrV secretion attenuates Yersinia pseudotuberculosis virulence. J Bacteriol 189: 8417-8429.
26. Mueller CA, Broz P, Muller SA, Ringler P, Erne-Brand F, et al. (2005) The Vantigen of Yersinia forms a distinct structure at the tip of injectisome needles. Science 310: 674-676.
27. Pettersson J, Holmstrom A, Hill J, Leary S, Frithz-Lindsten E, et al. (1999) The V-antigen of Yersinia is surface exposed before target cell contact and involved in virulence protein translocation. Mol Microbiol 32: 961-976.
28. Fields KA, Straley SC (1999) LcrV of Yersinia pestis enters infected eukaryotic cells by a virulence plasmid-independent mechanism. Infect Immun 67: 4801-4813.
29. DiMezzo TL, Ruthel G, Brueggemann EE, Hines HB, Ribot WJ, et al. (2009) In vitro intracellular trafficking of virulence antigen during infection by Yersinia pestis. PLoS ONE 4: e6281.
30. Weeks S, Hill J, Friedlander A, Welkos S (2002) Anti-V antigen antibody protects macrophages from Yersinia pestis-induced cell death and promotes phagocytosis. Microbial Path 32: 227-237.
31. Cowan C, Philipovskiy AV, Wulff-Strobel CR, Ye Z, Straley SC (2005) Anti- LcrV antibody inhibits delivery of Yops by Yersinia pestis KIM5 by directly promoting phagocytosis. Infect Immun 73: 6127-6137.
32. Doll JM, Zeitz PS, Ettestad P, Buchotz AL, Davis T, et al. (1994) Cattransmitted fatal pneumonic plague in a person who traveled from Colorado to Arizona. Am J Trop Med Hyg 51: 109-114.
33. Anderson GW, Leary SEC, Williamson ED, Titball RW, Welkos SL, et al. (1996) Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis. Infect Immun 64: 4580-4585.
34. Powell BS, Andrews GP, Enama JT, Jendrek S, Bolt C (2005) Design and testing for a nontagged F1-V fusion protein as vaccine antigen against bubonic and pneumonic plague. Biotechnol Prog 21: 1490-1510.
35. Zhu Z, Chakraborti S, He Y, Roberts A, Sheahan T, et al. (2007) Potent crossreactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci USA 104: 12123-12128.
36. Burton DR (2001) Overview: amplification of antibody genes. In: Barbas CF, Burton DR, Scott JK, Silverman GJ, eds. Phage display: a laboratory manual. Cold Spring Harbor, New York, NY: Cold Spring Harbor Laboratory Press.
37. Welkos SL, Davis KM, Pitt LM, Worsham PL, Friedlander AM (1995) Studies on the contribution of the F1 capsule-associated plasmid pFra to the virulence of Yersinia pestis. Contrib Microbiol Immunol 13: 299-305.